We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where MannKind Corporation (NASDAQ:MNKD) stands against the other diabetes stocks.
Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration
About 422 million people worldwide have diabetes, according to the WHO, and most of them live in low- or middle-income nations. Every year, diabetes directly causes 1.5 million deaths on average. Both the number of cases and the prevalence of diabetes have steadily increased during the last several decades. However, according to the International Diabetes Federation, there are currently 500 million people with diabetes globally, and that number is expected to rise by 25% by 2030 and 51% by 2045.
The continuous glucose monitor (CGM) is one type of medical equipment used to help manage diabetes, including type 1 and type 2. It is now a rapidly growing segment of diabetic care devices, and the market has increased significantly in recent years. According to GlobalData, the demand for sophisticated diabetes care products, such as insulin pumps, pens, and continuous glucose monitoring (CGM) devices, was projected to be valued at $21.8 billion in 2023. According to GlobalData’s forecasts, the market will grow at a compound annual growth rate (CAGR) of 6.34% to reach revenues of $33.4 billion by 2030.
There are now 97 goods in the CGM category, according to the GlobalData marketed products database. Only a small number of these devices are implantable sensors; the majority are conventional CGMs. The GlobalData pipeline products database indicates that 133 goods are either approved or in the development stage. According to the data, this market niche is growing rapidly and is a center for cutting-edge new technologies such as implantable CGMs.
AI is now being included in CGM technology. For instance, Roche unveiled Accu-Chek SmartGuide, a revolutionary predictive AI-powered CGM device. Roche Diabetes Care Chief Medical Officer Julien Boisdron described it as “a solution more than a CGM” at the introduction. He explained how the system, which includes a sensor and two algorithms, helps with prediction and data visualization.
Rising Demand for GLP-1 Medications: Opportunities and Challenges in Diabetes and Obesity Treatment
The management of diabetes and its related complications has entered a new era of opportunity. The combined issues of diabetes and obesity can be effectively treated with these innovative approaches. Glucagon-like peptide-1 (GLP-1) agonists are a class of medications used to treat type 2 diabetes mellitus (T2DM) and obesity. The GLP-1 market, which is driven equally by diabetes and obesity, is predicted to reach $100 billion by 2030. By this time, there could be 30 million GLP-1 users or around 9% of the US population.
According to the most recent KFF Health Tracking survey, 12% of adult Americans say they have used a GLP-1 medication at some point. In the past five years, 43% of GLP-1 prescription users had diabetes, and 22% of patients with obesity or overweight diagnoses also took the medication. Over the course of the past year, the percentage of adults who have heard “a little” or “a lot” about these medicines has climbed from 70% to 82%, while the percentage of adults who have heard “a lot” or “a lot” about them has increased from 19% to 32%.
However, the rising demand for these weight-loss and diabetes drugs has created challenges. The National Pharmacy Association (NPA) warned of a possible “explosion in the unlicensed sale of medication online.” Semaglutides, marketed under the name Ozempic, assist people with type 2 diabetes in controlling their blood sugar levels. However, they are also frequently used to aid in weight loss in certain nations, such as the US, where they are marketed under the name Wegovy.
NPA chairman Nick Kaye stated:
“Pharmacists remain deeply concerned that the current medicine shortages crisis could lead to an explosion in the unlicensed sale of medication online.”
Pixabay/Public Domain
Our Methodology
Our methodology involved identifying healthcare companies focused on diabetes treatment using a stock screener. From the resultant dataset, we selected those with stock prices under $10 and ranked them based on their share price as of the close of December 26.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A close-up of a doctor’s hand pressing on an inhaler, conveying the effect of the company’s therapeutic products.
MannKind Corporation (NASDAQ:MNKD)
Share Price as of the Close of December 26: $6.89
MannKind Corporation (NASDAQ:MNKD) develops inhaled therapies for diabetes, with Afrezza as its key product. This rapid-acting inhaled insulin mimics the body’s natural insulin response, working within 12-15 minutes and clearing in 2-3 hours for better blood sugar control. Its small, needle-free inhaler is easy to use, and pre-measured doses ensure accuracy. The company also earns revenue from Afrezza and other diabetes products like the V-Go insulin delivery device.
MannKind Corporation (NASDAQ:MNKD)’s Q3 2024 results highlight strong growth, with $70 million in total revenues, up 37% year-over-year, and $209 million year-to-date, a 49% increase. Net income reached $20 million, with a non-GAAP net income of $45 million, driven by strong Tyvaso DPI sales. The company holds $268 million in cash and investments and is advancing its clinical pipeline.
MannKind Corporation (NASDAQ:MNKD) has made significant strides in its clinical pipeline, expanding the MNKD-101 Phase 3 trial globally and completing the MNKD-201 Phase 1 trial. MNKD-101 also received the FDA Fast Track designation, potentially accelerating its development. The company’s upcoming plans include meeting with the FDA in early 2025 regarding MNKD-2011 and discussing a potential sNDA submission for Afrezza, based on six-month results from the INHALE-1 pediatric diabetes study. The corporation is also advancing two orphan lung programs, with MNKD-201 Phase 1 trial results expected in Q4 2024.
As of Q3 2024, 22 hedge funds held shares in the company, as tracked by the Insider Monkey database. The largest stakeholder was Nitorum Capital with stakes worth $57.6 million. Analysts also hold a consensus Strong Buy rating on the stock.
Overall MNKD ranks 9th on our list of the best diabetes stocks to buy under $10. While we acknowledge the potential of MNKD as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than MNKD but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
